

Published in final edited form as:

Bioorg Med Chem Lett. 2013 October 1; 23(19): . doi:10.1016/j.bmcl.2013.07.062.

Synthesis and antioxidant evaluation of (*S,S*)- and (*R,R*)-secoisolariciresinol diglucosides (SDGs)

Om P. Mishra^a, Nicholas Simmons^{b,§}, Sonia Tyagi^a, Ralph Pietrofesa^a, Vladimir V. Shuvaev^c, Roman A. Valiulin^b, Philipp Heretsch^{b,e,*}, K. C. Nicolaou^{b,d,e,*}, and Melpo Christofidou-Solomidou^{a,**}

^aDepartment of Medicine, Pulmonary Allergy and Critical Care Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

^bDepartment of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA

^cInstitute for Translational Medicine and Therapeutics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

^dDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA

^eDepartment of Chemistry, BioScience Research Collaborative, Rice University, Houston, TX 77030, USA

Abstract

Secoisolariciresinol diglucosides (SDGs) (*S,S*)-SDG-1 (major isomer in flaxseed) and (*R,R*)-SDG-2 (minor isomer in flaxseed) were synthesized from vanillin *via* secoisolariciresinol (**6**) and glucosyl donor **7** through a concise route that involved chromatographic separation of diastereomeric diglucoside derivatives (*S,S*)-**8** and (*R,R*)-**9**. Synthetic (*S,S*)-SDG-1 and (*R,R*)-SDG-2 exhibited potent antioxidant properties ($EC_{50} = 292.17 \pm 27.71 \mu\text{M}$ and $331.94 \pm 21.21 \mu\text{M}$, respectively) which compared well with that of natural (*S,S*)-SDG-1 ($EC_{50} = 275.24 \pm 13.15 \mu\text{M}$). These values are significantly lower than those of ascorbic acid ($EC_{50} = 1129.32 \pm 88.79 \mu\text{M}$) and α -tocopherol ($EC_{50} = 944.62 \pm 148.00 \mu\text{M}$). Compounds (*S,S*)-SDG-1 and (*R,R*)-SDG-2 also demonstrated powerful scavenging activities against hydroxyl [natural (*S,S*)-SDG-1: 3.68 ± 0.27 ; synthetic (*S,S*)-SDG-1: 2.09 ± 0.16 ; synthetic (*R,R*)-SDG-2: 1.96 ± 0.27], peroxy [natural (*S,S*)-SDG-1: 2.55 ± 0.11 ; synthetic (*S,S*)-SDG-1: 2.20 ± 0.10 ; synthetic (*R,R*)-SDG-2: 3.03 ± 0.04] and DPPH [natural (*S,S*)-SDG-1: $EC_{50} = 83.94 \pm 2.80 \mu\text{M}$; synthetic (*S,S*)-SDG-1: $EC_{50} = 157.54 \pm 21.30$; synthetic (*R,R*)-SDG-2: $EC_{50} = 123.63 \pm 8.67$] radicals. These results confirm previous studies with naturally occurring (*S,S*)-SDG-1 and establish both (*S,S*)-SDG-1 and (*R,R*)-SDG-2 as potent antioxidants and free radical scavengers for potential *in vivo* use.

© 2009 Elsevier Ltd. All rights reserved.

*Corresponding chemistry author. Tel.: +1-713-348-2698; kcn@rice.edu. **Corresponding biology author. Tel.: +1-215-573-9917; fax: +1-215-573-4469; melpo@mail.med.upenn.edu.

§The two first authors contributed equally to this work

Supplementary Data

Full synthetic details, compound characterization and descriptions of the biological assays may be found in the supplementary material.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Keywords

Antioxidant; SDG; Free radical scavenger; Flaxseed lignans; ROS

Secoisolariciresinol diglucoside [SDG, (*S,S*)-SDG-1] is a major component of the lignans in flaxseed (Figure 1).¹ Previous studies have shown that flaxseed (*S,S*)-SDG-1 is a potent antioxidant *in vitro* and *in vivo*,²⁻⁶ and a powerful *in vitro* scavenging agent against free hydroxyl radicals.⁷ Increased generation of reactive oxygen species (ROS) such as superoxide anion (O_2^-), hydroxyl radical ($\cdot OH$), and hydrogen peroxide leads to tissue damage under various pathological conditions.⁸⁻¹⁰ These species result in cellular damage through oxidative modification of cellular membrane lipids, proteins, and the genomic DNA.¹¹ Therefore, SDG as an antioxidant may have therapeutic potential under various experimental and disease conditions that are associated with oxidative tissue damage such as in cancer patients undergoing radiotherapy.

Ionizing radiation inflicts damage to biological systems through generation of reactive oxygen and nitrogen species (e.g. peroxidation of membrane lipids, oxidation and nitration of proteins, DNA and RNA strand breaks).¹² Antioxidant compounds that scavenge free radicals, enhance endogenous antioxidant enzyme levels, and boost DNA repair may be useful in countering radiation damage. Despite extensive research efforts toward the development of synthetic compounds as radioprotectors, there is still a need for safe and more effective agents. In view of their properties, natural products and their analogs are increasingly considered as promising leads for the discovery and development of radioprotectors.

Plants contain a plethora of secondary metabolites with wide-ranging pharmacological properties. Phenolic acids, flavonoids, and phenylpropanoids are the most prominent metabolite classes known for antioxidant activity.¹³ Dietary and medicinal plants possessing antioxidant properties have been shown to play an important role in preventing many human diseases associated with oxidative stress.^{14,15}

In previous studies, we have investigated the role of whole grain dietary flaxseed in radiation-induced damage.¹⁶⁻¹⁸ Flaxseed ameliorated the radiation-induced inflammation and oxidative stress in mice, and irradiated mice fed with flaxseed diets enriched with (*S,S*)-SDG-1 showed improved hemodynamic indices and survival over the control. Importantly, a flaxseed diet enriched in (*S,S*)-SDG-1 also improved polymorphonuclear cell infiltration and decreased lung inflammation, demonstrating its protective effects against radiation-induced lung damage *in vivo*.

Secoisolariciresinol (the aglycon of (*S,S*)-SDG-1 and (*R,R*)-SDG-2) has been of interest to several synthetic groups. A double Stobbe condensation¹⁹ has been used to prepare racemic secoisolariciresinol and enantioenriched secoisolariciresinols have been prepared from aldol reactions on chiral α -butyrolactones²⁰ as well as diastereoselective alkylation of Evans auxiliary appended hydroferulic acid derivatives.²¹ In a recent report the synthesis of (*S,S*)-SDG-1 was claimed.³

The synthesis of secoisolariciresinol diglucosides (*S,S*)-SDG-1 and (*R,R*)-SDG-2 proceeded from vanillin (**3**) as shown in Figure 2. Thus, following a modified literature procedure,¹⁹ **3** was subjected to Stobbe condensation with dimethyl succinate in the presence of lithium wire in refluxing methanol, and the resulting mixture of carboxylic acids was esterified with methanol under acidic conditions to furnish dimethyl ester **4** in 70% overall yield (single isomer, unassigned olefin geometry). A second Stobbe condensation involving product **4**

with vanillin under the same lithium-mediated conditions, followed by esterification with methanol under the same acidic conditions, led to diene **5** in 61% overall yield (single isomer, unassigned olefin geometry). The latter compound underwent diastereoselective hydrogenation (Pd/C, H₂, 84% yield), phenolic benzylation (NaH, BnBr, 95% yield), and ester reduction (LAH, 93% yield) to provide *bis*-benzyl secoisolariciresinol **6**. The relative stereochemistry of **6** was confirmed by X-ray crystallographic analysis (see Figure 3 for ORTEP representation). Attempts to attach the glucose moieties onto **6** employing peracetyl-protected glucosyl donors led predominately to acetylation of the primary hydroxyl groups of the substrate. The glycosidation of **6** was finally achieved through the use of the perbenzoyl-protected trichloroacetimidate **7**²² under the influence of TMSOTf, furnishing a diastereomeric mixture of inseparable *bis*-glucosides (88% combined yield, 1:1 *dr*). Cleavage of the benzyl ethers by hydrogenolysis provided a mixture of diastereomeric *bis*-phenols (86% yield, 1:1 *dr*) which proved separable by preparative thin layer chromatography (PTLC, multiple elutions) to afford pure (*S,S*)-**8** and (*R,R*)-**9**. Each perbenzoylated *bis*-glucoside was treated with NaOMe in MeOH to give the corresponding secoisolariciresinol diglucoside (*S,S*)-SDG-**1** (88% yield) and (*R,R*)-SDG-**2** (81% yield), whose spectral data matched those previously reported for these compounds.²³

As antioxidants, polyphenols and other lignan components have been reported to modulate the activity and expression of enzymes involved in reactive oxygen species detoxification, quench free radicals, and chelate transition metals, resulting in complexes which are redox inactive in the Fenton reaction.²⁴ Since such a compound may have diverse antioxidant properties, we chose to evaluate our synthetic agents using various assays.²⁵ In light of these observations, we proceeded to evaluate the reducing power of synthesized (*S,S*)-SDG-**1** and (*R,R*)-SDG-**2** as well as their free radical scavenging activity against hydroxyl, peroxy, and DPPH free radicals.

The reducing power of synthetic (*S,S*)-SDG-**1**, synthetic (*R,R*)-SDG-**2**, natural (*S,S*)-SDG-**1**, ascorbic acid, and α -tocopherol was determined by the reduction of K₃Fe(CN)₆ in the presence of FeCl₃, as measured by the absorbance of the resulting ferric-ferrous complex (Figure 4).²⁶ The reducing power of synthetic (*S,S*)-SDG-**1**, synthetic (*R,R*)-SDG-**2**, and natural (*S,S*)-SDG-**1** were significantly concentration-dependent at higher concentrations; however, at all concentrations tested the SDGs had comparable or higher reducing power than known antioxidants ascorbic acid and α -tocopherol, with a notable increase in potency in the 200–500 μ M range. A linear relationship between reducing power and substrate concentration was observed at lower concentrations (1–100 μ M), allowing regression line equations to be established for the five compounds. This allowed the half maximal effective concentration (EC₅₀) for reducing power to be calculated (Figure 5). The EC₅₀ (mean \pm std. dev.) values for (*S,S*)-SDG-**1** and (*R,R*)-SDG-**2** were 292.17 \pm 27.71 μ M and 331.94 \pm 21.21 μ M, respectively. These values were comparable to that of natural (*S,S*)-SDG-**1** (EC₅₀ = 275.24 \pm 13.15 μ M) but approximately three-fold higher than that exhibited by ascorbic acid (EC₅₀ = 1129.32 \pm 88.79 μ M) and α -tocopherol (EC₅₀ = 944.62 \pm 148.00 μ M).

The ability of synthetic (*S,S*)-SDG-**1** and (*R,R*)-SDG-**2** to scavenge hydroxyl and peroxy radicals as manifested by their inhibition of the oxidation of fluorescein was assessed by the hydroxyl radical averting capacity (HORAC, gallic acid standard) and peroxy radical absorbance capacity assays (ORAC, Trolox standard), respectively (Table 1). Fluorescein oxidation by hydroxyl radicals was decreased by synthetic (*S,S*)-SDG-**1** and synthetic (*R,R*)-SDG-**2** in a concentration-dependent manner and was found to be two-fold higher than gallic acid. However, synthetic (*S,S*)-SDG-**1** activity differed from natural (*S,S*)-SDG-**1**, likely due to trace impurities. Fluorescein oxidation by peroxy radicals generated using 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) was greatly reduced in the presence of synthetic

(*S,S*)-SDG-1, (*R,R*)-SDG-2 and natural (*S,S*)-SDG-1, with a two-fold increase in potency over the Trolox standard (Table 1).

The free radical scavenging activities of synthetic (*S,S*)-SDG-1 and (*R,R*)-SDG-2 were determined using a 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging assay and was compared to those of natural (*S,S*)-SDG-1, ascorbic acid, and α -tocopherol (Figure 6). At low (5–25 μM) and mid-concentration (50–100 μM) ranges, the SDGs exhibited similar scavenging potentials; however at higher concentrations (250–500 μM), the inhibition by synthetic (*S,S*)-SDG-1 was significantly lower than those exerted by (*R,R*)-SDG-2 and natural (*S,S*)-SDG-1. Establishing regression lines for the potentials at low- and mid-concentration ranges (5–100 μM) allowed the free radical EC_{50} scavenging activity of these compounds to be determined. As shown in Figure 7, synthetic (*R,R*)-SDG-2 ($123.63 \pm 8.67 \mu\text{M}$) and synthetic (*S,S*)-SDG-1 ($157.54 \pm 21.30 \mu\text{M}$) were not significantly different. These values were similar to those exhibited by natural (*S,S*)-SDG-1 ($83.94 \pm 2.80 \mu\text{M}$) and α -tocopherol ($132.81 \pm 12.57 \mu\text{M}$) but considerably lower than that shown by ascorbic acid ($439.56 \pm 11.81 \mu\text{M}$). These results are comparable to those recently reported for SDG.³

In summary, we have synthesized (*S,S*)-SDG-1 and (*R,R*)-SDG-2 and characterized their antioxidant properties. Both possess strong reducing power and high free radical scavenging activity for hydroxyl, peroxy and DPPH free radicals. Synthetic (*S,S*)-SDG-1 and (*R,R*)-SDG-2 have been shown to be promising agents for use in modulating cellular redox states and for scavenging oxygen free radicals *in vivo*. Efforts are currently underway to develop scalable synthetic routes to (*S,S*)-SDG-1, (*R,R*)-SDG-2 and related analogs. Further *in vitro* and *in vivo* studies to determine the mechanism of action and usefulness of the SDGs as antioxidants and protectors against radiation-induced tissue damage are in progress.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Drs. D.H. Huang, L. Pasternack, and R. Chadha for NMR spectroscopic and X-ray crystallographic assistance. This work was funded in part by The Skaggs Institute for Research, the National Science Foundation (graduate fellowship to N.S.), Merck (postdoctoral fellowship to R.A.V.), the Deutsche Akademie der Naturforscher Leopoldina (postdoctoral fellowship to P.H.), NIH-R01 CA133470 (M.C.S.), NIH-RC1AI081251 (M.C.S.), the University of Pennsylvania Research Foundation (M.C.S.) and by pilot project support from 1P30 ES013508-02 awarded to M.C.S. (its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIEHS, NIH).

References and notes

1. Axelson M, Sjoval J, Gustafsson BE, Setchell KDR. *Nature*. 1982; 298:659. [PubMed: 6285206]
2. Kitts DD, Yuan YV, Wijewickreme AN, Thompson LU. *Mol Cell Biochem*. 1999; 202:91. [PubMed: 10705999]
3. Moree S, Khanum SA, Rajesha J. *Free Rad Antiox*. 2011; 1:31.
4. Hu C, Yuan YV, Kitts DD. *Food Chem Toxicol*. 2007; 45:2219. [PubMed: 17624649]
5. Moree SS, Rajesha J. *Mol Cell Biochem*. 2013; 373:179. [PubMed: 23108790]
6. Rajesha J, Murthy KN, Kumar MK, Madhusudhan B, Ravishankar GA. *J Agric Food Chem*. 2006; 54:3794. [PubMed: 16719498]
7. Prasad K. *Mol Cell Biochem*. 1997; 168:117. [PubMed: 9062900]
8. Adolphe JL, Whiting SJ, Juurlink BH, Thorpe LU, Alcorn J. *Br J Nutr*. 2010; 103:929. [PubMed: 20003621]
9. Seifried HE. *J Nutr Biochem*. 2007; 18:168. [PubMed: 17296489]

10. Seifried HE, Anderson DE, Fisher EI, Milner JA. *J Nutr Biochem*. 2007; 18:567. [PubMed: 17360173]
11. Halliwell B. *Free Radical Biol Med*. 1989; 7:645. [PubMed: 2695408]
12. Riley PA. *Int J Radiat Biol*. 1994; 65:27. [PubMed: 7905906]
13. Rice-Evans CA, Miller NJ. *Biochem Soc Trans*. 1996; 24:790. [PubMed: 8878849]
14. Scalbert A, Johnson IT, Saltmarsh M. *Am J Clin Nutr*. 2005; 81:215S. [PubMed: 15640483]
15. Scalbert A, Manach C, Morand C, Remesy C, Jimenez L. *Crit Rev Food Sci Nutr*. 2005; 45:287. [PubMed: 16047496]
16. Pietrofesa R, Turowski J, Tyagi S, Dukes F, Arguiri E, Busch TM, Gallagher-Colombo SM, Solomides CC, Cengel KA, Christofidou-Solomidou M. *BMC Cancer*. 2013; 13:179. [PubMed: 23557217]
17. Christofidou-Solomidou M, Tyagi S, Pietrofesa R, Dukes F, Arguiri E, Turowski J, Grieshaber PA, Solomides CC, Cengel KA. *Radiat Res*. 2012; 178:568. [PubMed: 23106213]
18. Lee JC, Krochak R, Blouin A, Kanterakis S, Chatterjee S, Arguiri E, Vachani A, Solomides CC, Cengel KA, Christofidou-Solomidou M. *Cancer Biol Ther*. 2009; 8:47. [PubMed: 18981722]
19. Lee E, Ahamed VSJ, Kumar MS, Rhee SW, Moon SS, Hong IS. *Bioorg Med Chem Lett*. 2011; 21:6245. [PubMed: 21958542]
20. Yamauchi S, Sugahara T, Matsugi J, Someya T, Masuda T, Kishida T, Akiyama K, Maruyama M. *Biosci Biotechnol Biochem*. 2007; 71:2283. [PubMed: 17827687]
21. Allais F, Pla TJL, Ducrot P. *Synthesis*. 2011; 9:1456.
22. Mühlhausen U, Schirrmacher R, Piel M, Lecher B, Briegert M, Piee-Staffa A, Kaina B, Rösch F. *J Med Chem*. 2006; 49:263. [PubMed: 16392811]
23. For (S,S)-SDG-1: Chimichi S, Bambagiotti-Alberti M, Coran SA, Giannellini V, Biddau B. *Magn Reson Chem*. 1999; 37:860. Qiu S, Lu Z, Luyengi L, Lee SK, Pezzuto JM, Farnsworth NR, Thompson LU, Fong HHS. *Pharm Biol*. 1999; 37:1. For (R,R)-SDG-2: Ford JD, Huang K, Wang H, Davin LB, Lewis NG. *J Nat Prod*. 2001; 64:1388. [PubMed: 11720519] Ford JD, Huang K, Wang H, Davin LB, Lewis NG. *J Nat Prod*. 2002; 65:800.
24. Heim KE, Tagliaferro AR, Bobilya DJ. *J Nutr Biochem*. 2002; 13:572. [PubMed: 12550068]
25. Prior RL, Cao G. *Free Radical Biol Med*. 1999; 27:1173. [PubMed: 10641708]
26. Yen GC, Pin-Der D. *J Am Oil Chem Soc*. 1993; 70:383.




Figure 1.
Molecular structures of secoisolariciresinol diglucosides (*S,S*)-SDG-1 and (*R,R*)-SDG-2.




Figure 2. Synthesis of secoisolariciresinol diglucosides **(S,S)-SDG-1** and **(R,R)-SDG-2**. For details see supplementary data.




Figure 3.
ORTEP representation of dihydroxy compound **6** (CCDC-940963).




Figure 4.

Reducing power of synthetic (*S,S*)-SDG-1 and (*R,R*)-SDG-2. The increase in absorbance at 700nm indicates increase in reducing power. The results are presented as mean \pm standard deviation ($n = 3$). * $p < 0.05$ significantly lower than natural (*S,S*)-SDG-1, synthetic (*R,R*)-SDG-2, and synthetic (*S,S*)-SDG-1; ** $p < 0.05$ significantly higher than synthetic (*R,R*)-SDG-2, synthetic (*S,S*)-SDG-1, ascorbic acid and α -tocopherol. The somewhat higher potency of natural (*S,S*)-SDG-1 may be due to an unknown impurity in our samples, however the NMR spectra of both natural and synthetic (*S,S*)-SDG-1 did not reveal major impurities.




Figure 5. Reducing power of synthetic (*S,S*)-SDG-1 and (*R,R*)-SDG-2. The rate of reaction is linear in the concentration range of 1–100 µM. Equation of the linear regression was used to determine EC₅₀. The results are presented as mean ± standard deviation (n = 3). Natural (*S,S*)-SDG-1, synthetic (*R,R*)-SDG-2, and synthetic (*S,S*)-SDG-1 were not significantly different from each other. **p* < 0.05 significantly higher than natural (*S,S*)-SDG-1, synthetic (*R,R*)-SDG-2, and synthetic (*S,S*)-SDG-1.




Figure 6. DPPH free radical scavenging activity of natural (*S,S*)-SDG-1, synthetic (*S,S*)-SDG-1 and (*R,R*)-SDG-2, ascorbic acid, and α -tocopherol. The radical scavenging activity was measured as a decrease in the absorbance of DPPH at 517 nm. The results are presented as mean \pm standard deviation ($n = 3$). * $p < 0.05$ significantly lower than all other compounds, ** $p < 0.05$ significantly lower than natural (*S,S*)-SDG-1.




Figure 7. DPPH free radical scavenging activity of natural (*S,S*)-SDG-1, synthetic (*S,S*)-SDG-1 and (*R,R*)-SDG-2, ascorbic acid, and α -tocopherol. Equation of the linear regression was used to determine EC₅₀. The rate of reaction is linear in the concentration range of 1–100 μ M. The results are presented as mean \pm standard deviation ($n = 3$). Natural (*S,S*)-SDG-1, synthetic (*R,R*)-SDG-2, synthetic (*S,S*)-SDG-1, and α -tocopherol were not significantly different. * $p < 0.05$ significantly higher than natural (*S,S*)-SDG-1, synthetic (*R,R*)-SDG-2, synthetic (*S,S*)-SDG-1, and α -tocopherol.

Table 1

Antioxidant capacity of synthetic (*S,S*)-SDG-1 and (*R,R*)-SDG-2. Hydroxyl radicals were generated from hydrogen peroxide by Fenton reaction. Peroxyl radicals were generated by AAPH (2,2 -azobis(2-amidinopropane) dihydrochloride). Oxidation of fluorescein was measured. Calculations used SDG concentrations that fitted the linear part of the calibration curve. The results are presented as mean \pm standard deviation ($n = 3$). The somewhat higher potency of natural (*S,S*)-SDG-1 may be due to an unknown impurity in our samples, however the NMR spectra of both natural and synthetic (*S,S*)-SDG-1 did not reveal major impurities.

Entry	Antioxidant	Against Hydroxyl ^a Radicals (GAE) ^c	Against Peroxyl ^b Radicals (TE) ^d
1.	natural (<i>S,S</i>)-SDG-1	3.68 \pm 0.27	2.55 \pm 0.11
2.	synthetic (<i>R,R</i>)-SDG-2	1.96 \pm 0.27	2.20 \pm 0.10
3.	synthetic (<i>S,S</i>)-SDG-1	2.09 \pm 0.16	3.03 \pm 0.04

^aDetermined by HORAC Assay;

^bDetermined by ORAC Assay;

^cGallic acid equivalents;

^dTrolox equivalents.